Add-on effects of suplatast tosilate in bronchial asthma patients treated with inhaled corticosteroids

Lung

Volumn 181, Issue 4, 2003, Pages 227-235

  Sano, T ^a   Nakamura, Y ^b   Yanagawa, H ^c   Bando, H ^a   Nii, A ^d   Yoshida, S ^e   Sone, S ^c  

^a TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b National Hospital Organization   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d Nishikagawa Hospital   (Japan)

^e National Hospital Organization   (Japan)

Author keywords

Additive effect; Bronchial asthma; Inhaled corticosteroids; Suplatast tosilate; Th2 cytokines

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYTOKINE; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; SUPLATAST TOSYLATE;

ADULT; AGED; ARTICLE; ASTHMA; ATOPY; BLOOD CELL COUNT; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; EOSINOPHIL; EXPIRATORY FLOW; HUMAN; INFLAMMATION; INFORMED CONSENT; LIVER TOXICITY; LUNG FUNCTION; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADMINISTRATION, INHALATION; ADULT; ANTI-ASTHMATIC AGENTS; ARYLSULFONATES; ASTHMA; BECLOMETHASONE; CYTOKINES; HISTAMINE ANTAGONISTS; HUMANS; PEAK EXPIRATORY FLOW RATE; SULFONIUM COMPOUNDS; TH2 CELLS;

EID: 0141729357     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-003-1025-y     Document Type: Article

References (25)

1. American Thoracic Society (1987) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 136:225-244
2. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL (1993) A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J 6:877-885
3. Barnes PJ (1995) Inhaled glucocorticoids for asthma. N Engl J Med 332:868-875
4. Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, Richard KA (2001) Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 120:423-430
5. Gonzalo JA, Lloyd CM, Kremer L, Finger E, Martinez AC, Siegelman MH, Cybulsky M, Gutierrez Ramos JC (1996) Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J Clin Invest 98:2332-2345
6. Greening AP, Ind PW, Northfeld M, Shaw G, on behalf of Allen & Hanburys Limited UK Study Group (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms of existing inhaled corticosteroid. Lancet 344:219-224
7. Horiguchi T, Tachikawa S, Handa M, Hanazono K, Kondo R, Ishibashi A, Banno K (2001) Effects of suplatast tosilate on airway inflammation and airway hyperresponsiveness. J Asthma 38:331-336
8. Iijima H, Tamura G, Hsiue TR, Liu Y, Taniguchi H, Shirato K (1999) Suplatast tosilate inhibits late response and airway inflammation in sensitized guinea pigs. Am J Respir Crit Care Med 160:331-335
9. Koda A, Yanagihara Y, Matsuura N (1991) IPD-1151T: a prototype drug of IgE antibody synthesis modulation. Agents Actions 34:369-378
10. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF for the Montelukast/Beclomethasone additivity Group (1999) Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 160:1862-1868
11. Lukacs NW, Strieter RM, Chensue SW, Kunkel SL (1994) Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J Respir Cell Mol Biol 10:526-532
12. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348-2357
13. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Richard K, Knobil K (2000) Fluticasone propionate/salmeterol combination provide more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106:1088-1095
14. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A, for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337:1405-1411
15. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB (1992) Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326:298-304
16. Sano Y, Miyamoto T, Makino S (1997) Anti-inflammatory effect of suplatast tosilate on mild asthma. Chest 112:862-863
17. Suissa S, Ernst P (2001) Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 107:937-944
18. Suwaki T, Agrawal DK, Townley RG (2001) Modification of eosinophil function by suplatast tosilate (IPD), a novel anti-allergic drug. Int Immunopharmacol 1:2163-2171
19. Tamaoki J, Kondo M, Sakai N, Aoshiba K, Tagaya E, Nakata J, Isono K, Nagai A, on behalf of Tokyo Joshi-Idai Asthma Research Group (2000) Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomized study. Lancet 356:273-278
20. Taniguchi H, Togawa M, Ohwada K, Kiniwa M, Matsuura N, Nagai H, Koda A (1996) Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs. Eur J Pharmacol 318:447-454
21. Wierenga EA, Snoke M, Jansen HM, Bos JD, von Lier RAW, Kapsenberg ML (1991) Human atopen-specific types 1 and 2 T helper cell clones. J Immunol 147:2942-2949
22. Yamaya H, Basaki Y, Togawa M, Kojima M, Kiniwa M, Matsuura N (1995) Down-regulation of Th2 cell-mediated murine peritoneal eosinophilia by antiallergic agents. Life Sci 19:1647-1654
23. Yanagihara Y, Kiniwa M, Ikizawa K, Yamaya H, Sida T, Matsuura N, Koda A (1993) Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: I Regulation of murine IgE response. Jpn. J Pharmacol 61:23-30
24. Yanagihara Y, Kiniwa M, Ikizawa K, Sida T, Matsuura N, Koda A (1993) Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: II Regulation of human IgE response. Jpn J Pharmacol 61:31-39
25. Zhao GD, Yokoyama A, Kohno N, Sakai K, Hamada H, Hiwada K (2000) Effect of suplatast tosilate (IPD-1151T) on a mouse model of asthma: inhibition of eosinophilic inflammation and bronchial hyperresponsiveness. Int Arch Allergy Immunol 121:116-122